UK-390957

UK‑390957 is an investigational small molecule drug developed as a selective serotonin reuptake inhibitor (SSRI) for the treatment of premature ejaculation. It was designed to provide on-demand dosing with rapid onset and short half-life, aiming to improve intravaginal ejaculatory latency time (IELT), ejaculatory control, and sexual satisfaction while minimizing adverse effects. The drug reached phase II/III clinical development but was ultimately discontinued. Its mechanism of action involves inhibition of the serotonin transporter (SERT), increasing synaptic serotonin levels in the central nervous system to delay ejaculation[2][4][7].

Other names

364321-71-1934301-71-0W26I0D1D6JW-26I0D1D6JW 26I0D1D6JDB11719DB-11719DB 11719CHEMBL505147CHEMBL-505147CHEMBL 505147